Dr. Loeb Discusses the Controversy of Screening and Treatment in Prostate Cancer

September 10, 2015
Stacy Loeb, MD

Stacy Loeb, MD, assistant professor, Urology and Population Health, NYU Langone Medical Center, discusses the controversy of screening and treatment in men with prostate cancer, as well as data from the National Prostate Cancer Register (NPCR) of Sweden.

Stacy Loeb, MD, assistant professor, Urology and Population Health, NYU Langone Medical Center, discusses the controversy of screening and treatment in men with prostate cancer, as well as data from the National Prostate Cancer Register (NPCR) of Sweden.

There is an issue of overtreatment for patients with low-risk disease, says Loeb. If a patient has low-risk prostate cancer, their risk of dying from the disease within 10-15 years is very low.

However, men in their 70s who have high-risk disease are currently being undertreated, continues Loeb. She believes some of the controversy has led to a consequence of reluctance to giving appropriate, curative treatment to healthy men in their 70s.